Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

NCT06193889 is registered in ClinicalTrials.gov with Kyverna Therapeutics as lead sponsor.

NCT NCT06193889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
Lead sponsor
Kyverna Therapeutics
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 28, 2024
Completion date
September 30, 2028
Enrollment
66 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis, myasthenia gravis